# Instructions

|  |  |
| --- | --- |
| ***Organization Name:*** |  |
|  |  |
| ***Date Completed:*** |  |
|  |  |
| ***Purpose:*** | To evaluate existing resources and processes and identify areas of improvement to facilitate interventions to reduce the incidence and prevalence of infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA), the primary goal of participation in the AHRQ Safety Program for MRSA Prevention. |
| ***Outcome:*** | This gap analysis will be completed twice, once at the beginning and once at the end of participation in the AHRQ Safety Program. When completed at the start of the Safety Program, it will be used by the project team to understand needs of participating facilities and by participating facilities to prioritize areas for improvement and advocate for resources. When completed at the end of the Safety Program, both the project team and the participating facilities will use the gap analysis to assess progress in building infrastructure and capacity to sustainably reduce MRSA infections. |
| ***Instructions:*** | This gap analysis addresses infection control activities, specifically those related to MRSA prevention, in the participating facility and should be completed by the Project Lead for the participating facility in collaboration with the infection preventionist lead (if the Project Lead is not the infection preventionist). For each item, enter answers directly into the data portal in the indicated space. For some items, there will be a dropdown menu to allow you to select your answers. |

Public reporting burden for the collection of information is estimated to average 1 hour per response. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: AHRQ Reports Clearance Officer, Attention: PRA, Paperwork Reduction Project (0935-0143), AHRQ, 5600 Fishers Lane, MS 0741A, Rockville, MD 20857.

The confidentiality of your responses is protected by Sections 944(c) and 308(d) of the Public Health Service Act [42 U.S.C. 299c-3(c) and 42 U.S.C. 242m(d)]. Information that could identify you will not be disclosed unless you have consented to that disclosure.

|  |  |
| --- | --- |
| ***Item Description*** | ***Response*** |
| **INFECTION PREVENTION PROGRAM STRUCTURE AND RESOURCES** | |
| **Facility Characteristics and Staffing** | |
| Please indicate what type of service(s) your facility provides for residents. (select all that apply) | * Long-term general nursing care * Long-term dementia care * Skilled nursing care * Short-term (subacute) rehabilitation * Long-term psychiatric care * Ventilator care * Bariatric care * Hospice or palliative care * On-site Hemodialysis Center * Comprehensive wound care * Other: \_\_\_\_\_\_\_\_\_\_\_ |
| What is your facility’s capacity? | Fill in Answers:   * Total Beds: * Average Census: * Percentage of Short-Stay residents: * Number of single rooms: * Number of triple or quad rooms: * Number of ventilator care beds: |
| Facility ownership | Select:   * Hospital owned * Non-Hospital owned but part of larger health system * Independent |
| Facility Payment Structure | Select:   * For Profit * Not-for-Profit |
| Please describe your Staffing Ratios | Fill in answers:  *For Skilled/Short-stay/Vent units*   * Registered nurse (RN)-to-Resident: * Certified nursing assistant (CNA)-to-Resident: * Respiratory therapist (RT)-to-Resident (if applicable):   *For Long-Term Units:*   * RN-to-Resident: * CNA-to-Resident: |
| Does your facility have a specific person with dedicated time who is responsible for coordinating the infection control program? | Yes / No |
| If yes, how many fulltime equivalents (FTEs) of this person are allocated to infection control activities? |  |
| If yes, has this person received specific training in infection control? | Yes / No |
| If yes, where was the training? |  |
| If yes, when was the training? | * Within a year * 1-5 years ago * 6-10 years ago * > 10 years ago |
| If yes to having a specific person who is responsible for the infection control program, does that person have access to an physician who can provide technical support regarding healthcare epidemiology and infection prevention issues? | * No * Yes, full-time * Yes, part-time. |
| If yes to having an infectious diseases physician available to the infection prevention program, how often are they available to provide this support? | * Not available * Rarely * Usually * Always |
| **Senior Leadership** | |
| To whom in senior leadership does the infection prevention program (or infection preventionist if there is no program) report? Please provide the leader’s position title/role or department, not a specific individual’s name. |  |
| How often does infection prevention meet with senior leadership? | * Weekly * Monthly * Quarterly * Annually * Never * Other: \_\_\_\_\_\_\_\_\_\_\_ |
| Does senior leadership actively promote/support infection prevention activities? (check all that apply) | * No * Yes: Participates as an Infection Control Committee member * Yes: Provides adequate funding for infection prevention * Yes: Provides funding for infection prevention member training * Yes: Promotes infection prevention messages via newsletters, communications, screen savers, etc. * Yes: Provides back up to the infection prevention program if employees do not follow policies and procedures * Yes: Other: \_\_\_\_\_\_\_\_\_\_\_\_ |
| Is there a team or committee that reviews infection-control related activities? | Yes / No |
| If yes, please name members (I.e. charge nurse, administrator, Assistant Director of Nursing (ADON)) |  |
| If yes, at what intervals does this team meet? | * Daily * Weekly * Monthly * Quarterly * Annually |
| **Data Analysis and Management** | |
| Is a data analyst available to assist with obtaining, managing, analyzing, and reporting infection prevention data? | * No * Yes, full-time * Yes, part-time. |
| Is access to data analyst support adequate to meet program goals? | Yes / No |
| Select existing methods of storing infection data. (check all that apply) | * Paper * Microsoft Excel or other spreadsheet * Microsoft Access or other relational database * Software that is part of the electronic health record system * Standalone infection prevention software * Other: (describe) |
| Which of the following Infection Prevention data is submitted to the Centers for Disease Control and Prevention (CDC)/National Healthcare Safety network (NHSN)? (check all that apply) | * Multidrug resistant organism (MDRO) LabID * *Clostridioides difficile* (*C. difficile*) * Prevention process measures for hand hygiene * Prevention process measures for enhanced barrier precautions * Catheter-associated urinary tract infection (UTI) * Annual facility survey * Other: \_\_\_\_\_\_\_\_\_\_\_ * None |
| **Microbiology** | |
| Is there access to a microbiology laboratory that performs microbiology tests? | Yes / No |
| Does the infection prevention team have access to microbiology results? | Yes / No |
| Is there a system for the lab to alert the infection control team about epidemiologically important microbiology results? (check all that apply) | * Yes, cultures or tests positive for methicillin-resistant *Staphylococcus aureus* (MRSA) * Yes, cultures or tests positive for other epidemiologically important results (e.g. carbapenem resistant Enterobacterales (CRE), extended-spectrum beta-lactamase (ESBL) producing organisms, *C. difficile,*etc.) * No, there is no system in place to alert about these organisms |
| Is there a system for the lab to alert units in the facility about epidemiologically important microbiology results? (check all that apply) | * Yes, cultures or tests positive for MRSA * Yes, cultures or tests positive for other epidemiologically important results (e.g. carbapenem resistant Enterobacterales (CRE), extended-spectrum beta-lactamase (ESBL) producing organisms, *C. difficile,*etc.) * No, there is no system in place to alert about these organisms |
| Does your lab have the capacity, either in the facility or by sending the samples out to a reference lab, to process surveillance cultures? | Yes / No |

|  |  |
| --- | --- |
| **Surveillance and Prevention Activities** | |
| ***Epidemiologically Significant Bacteria*** | |
| General Questions | |
| When a resident is transferred from your facility to a different facility (e.g., acute care hospital), is there a system or policy in place for your facility to provide information to the receiving facility about whether the resident is colonized or infected with MRSA, other multidrug-resistant organisms, and/or *C. difficile*? (check all that apply) | * Yes, MRSA * Yes, antimicrobial-resistant Gram negative organisms * Yes, *C. difficile* * Yes, other: * No |
| When a resident is admitted or transferred to your facility, how often are you provided information about whether the resident is colonized or infected with MRSA, other multidrug-resistant organisms, and/or *C. difficile*. | * Always * Often * Sometimes * Almost Never * Never |
| If your facility is notified that a resident admitted or transferred to your facility is colonized or infected with MRSA or other multidrug-resistant organisms, please indicated how that notification is generally made. (select all that apply) | * A transfer form is completed and sent to the facility * A verbal report is made conveying the information * The information is noted in the medical record and flagged to draw attention to it * Other: |
| Methicillin-resistant *Staphylococcus aureus* (MRSA) | |
| Are residents who are colonized or infected with MRSA identified by the infection control team as soon as the relevant microbiology results are confirmed? | Yes / No |
| Are residents colonized or infected with MRSA placed on either contact isolation precautions or enhanced barrier precautions which require gowns and gloves for interactions with residents in their room? | * Yes, all residents * Yes, only residents with active MRSA infection * Yes, only residents with higher risk of transmission (e.g., draining wounds, presence of an indwelling device) * No |
| If yes, is there a system in place to monitor compliance with contact isolation precautions or enhanced barrier precautions? | * Yes, the unit measures compliance * Yes, infection prevention measures compliance * No |
| If yes, how often is feedback about compliance provided to the unit? (check all that apply) | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Is active surveillance for MRSA performed (e.g., obtaining nasal swabs for culture at set timepoints and/or repeating intervals following facility admission based on an established schedule)? | * Yes, all residents * Yes, select residents (specify): * Yes, other: * No |
| If yes, at what timepoints or with what frequency does active surveillance for MRSA occur? (check all that apply) | * On admission * Weekly * Upon discharge * Other: |
| If yes, is there a system in place to monitor compliance with obtaining MRSA surveillance swabs? | Yes / No |
| If yes, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| If yes, are rates of facility transmissions calculated (e.g., residents who have negative surveillance cultures on admission and develop MRSA colonization infection subsequently during the admission)? | Yes / No |
| If yes, are rates fed back to unit(s)? | Yes / No |
| If yes, indicate frequency: | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Do most or all residents in the facility receive chlorhexidine (CHG) treatment (bathing)? | Yes / No |
| If yes to most or all residents receiving CHG bathing, indicate the usual frequency of CHG bathing. | * Daily * Every other day * Weekly * Other: |
| If yes to most or all residents receiving CHG bathing, estimate the proportion of patients who actually receive the intended treatment. | * 100% * 75-99% * 50-74% * 25-49% * <25% |
| If yes to most or all residents receiving CHG bathing,, is there a system in place to monitor compliance with CHG bathing? | * Yes, the unit measures compliance * Yes, infection prevention measures compliance * Yes, both the unit and infection prevention measure compliance * No |
| If yes, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| If no to most or all residents receiving CHG bathing,, is CHG treatment (bathing) performed for residents with central lines or epidural catheters? | Yes / No |
| If yes to CHG bathing for patients with central lines or epidural catheters, indicate frequency: | * Daily * Every other day * Weekly * Other: |
| If yes to CHG bathing for patients with central lines or epidural catheters, estimate the proportion of residents with central lines or epidural catheters who actually receive the treatment. | * 100% * 75-99% * 50-74% * 25-49% * <25% |
| If yes to CHG bathing for patients with central lines or epidural catheters, is there a system in place to monitor compliance? | * Yes, the unit measures compliance * Yes, infection prevention measures compliance * Yes, both the unit and infection prevention measure compliance * No |
| If yes to CHG bathing for patients with central lines or epidural catheters, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Do most or all residents in the facility receive nasal decolonization ? | * Yes, with Mupirocin * Yes, with iodophor * No |
| If yes indicate frequency: (check all that apply) | * Twice daily for 5 days at the time of facility admission   Every other week for 5 days   * Other: |
| If yes to most or all residents in the facility receiving nasal decolonization, is there a system in place to monitor compliance? | * Yes, the unit measures compliance * Yes, infection prevention measures compliance * Yes, both the unit and infection prevention measure compliance * No |
| If yes to most or all residents in the facility receiving nasal decolonization, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| If no to most or all residents in the facility receiving nasal decolonization, is nasal decolonization performed for residents with MRSA infection or colonization? | * Yes, with Mupirocin * Yes, with iodophor * No |
| If yes to nasal decolonization performed for residents with MRSA infection or colonization, indicate frequency: (check all that apply) | * Twice daily for 5 days at the time of facility admission * Every other week for 5 days * Other: |
| If yes to nasal decolonization performed for residents with MRSA infection or colonization, is there a system in place to monitor compliance? | * Yes, the unit measures compliance * Yes, infection prevention measures compliance * Yes, both the unit and infection prevention measure compliance * No |
| If yes, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Carbapenem-resistant Enterobacterales (CRE) and Extended-Spectrum Beta-lactamase Producing (ESBL) Organisms | |
| Are residents who are colonized or infected with CREs and/or ESBL-producing organisms identified by the infection control team at the time that the microbiology results are confirmed? | Yes / No |
| Are residents colonized or infected with CREs and/or ESBL-producing organisms placed on contact isolation precautions or enhanced barrier precautions which require gowns and gloves for interactions with residents in their room? | * Yes, all residents * Yes, only residents with active infection * Yes, only residents with higher risk of transmission (e.g., draining wounds, diarrhea, presence of an indwelling device) * No |
| ***Device Related HAIs*** | |
| Central line-associated bloodstream infection (CLABSI) | |
| Does your facility admit residents with central lines (including any of the following: dialysis catheters, accessed ports, tunneled catheters, temporary non-tunneled central lines, or peripherally inserted central catheters (PICCs)?) | * Yes – Proceed to the following questions about central line-associated bloodstream infection (CLABSI) * No – Skip the next section on CLABSI and proceed to the following questions about hand hygiene that begin on the bottom of page 9. |
| If your facility admits residents with central lines, is surveillance for CLABSI performed? | Yes / No |
| If yes to performing CLABSI surveillance, is it done via chart review, electronically by extracting data from the electronic health record or billing codes without chart review, or a combination of chart review and electronic data extraction? | * Via chart review * Electronically by extracting data from the electronic health record or billing codes without chart review * Combination of both chart review and electronically by extracting data from the electronic health record or billing codes |
| If yes to performing CLABSI surveillance, are the CLABSI data fed back to units? | Yes / No |
| If yes to providing CLABSI data to the units, indicate frequency: | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| If your facility admits residents with central lines, does the facility focus on implementation of evidence-based practices for prevention of central line associated bloodstream infection (CLABSI) during central line maintenance? | Yes / No |
| If yes, indicate which of the following elements are included: (check all that apply) | * Scrub the hub with friction before each use with an appropriate antiseptic * Use sterile devices to access catheter * Replace dressing that are wet, soiled or loose * Routine sterile dressing changes * Change administration sets with recommended frequency based on circumstances |
| If yes, is there a system in place to monitor compliance? | * Yes, the unit measures compliance * Yes, infection prevention measures compliance * Yes, both the unit and infection prevention measure compliance * No |
| If yes, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| ***Hand Hygiene*** | |
| Does the infection prevention program have a surveillance program in place to assess compliance with hand hygiene? | Yes / No |
| If yes, what are the elements of the program (check all that apply)? | * Secret observations by unit staff * Secret observations by individual not from the unit * Observations followed by immediate feedback * An electronic monitoring system * Other (specify) |
| Are reports on compliance with hand hygiene developed and disseminated? | Yes / No |
| Is feedback regarding hand hygiene compliance provided to units? | Yes / No |
| If yes, indicate frequency: | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Do staff at your facility receive training on performance of hand hygiene (check all that apply)? | * Yes, on hire * Yes, annually * Yes, other interval: * No |
| Do staff at your facility receive competency validation on performance of hand hygiene (check all that apply)? | * Yes, on hire * Yes, annually * Yes, other interval: * No |
| ***Personal Protective Equipment*** | |
| Does the infection prevention program assess compliance with the use of contact isolation precautions or enhanced barrier precautions and the proper use of personal protective equipment? | Yes / No |
| If yes, what are the elements of the program? (check all that apply) | * Observations by unit staff * Observations by individual not from the unit * Observations followed by immediate feedback * Other (specify) |
| Are reports on compliance with use of personal protective equipment developed and disseminated? | Yes / No |
| Is feedback regarding use of personal protective equipment compliance provided to units? | Yes / No |
| If yes, indicate frequency: | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Do staff at your facility receive training on use of personal protective equipment (check all that apply)? | * Yes, on hire * Yes, annually * Yes, other interval: * No |
| Do staff at your facility receive competency validation on use of personal protective equipment (check all that apply)? | * Yes, on hire * Yes, annually * Yes, other interval: * No |
| Does your facility have a system to ensure that personal protective equipment supplies (e.g., gloves, gowns, masks) readily available and restocked? | Yes / No |
| ***Environmental Cleaning*** | |
| Does the infection prevention program have a surveillance program in place to assess compliance with cleaning of high-touch surfaces for both daily and discharge cleaning? | Yes / No |
| If yes, indicate which of the following are implemented: (check all that apply) | * Observations of cleaning * Application of fluorescent gel markers with follow up to see if markers are removed with cleaning * Assessment of surface contamination with ATPase * Other: |
| If yes, are reports on compliance with environmental cleaning developed and disseminated? | Yes / No |
| If yes, how often is feedback about compliance provided to the unit? | * Weekly * Monthly * Quarterly * Other: * Feedback not provided |
| Do staff at your facility receive training on environmental cleaning (check all that apply)? | * Yes, on hire * Yes, annually * Yes, other interval: * No |
| If yes, does it include the following (check all that apply): | * Review of appropriate disinfectants for various situations * Review of contact times of disinfectants * Review of what order to clean in |
| Do staff at your facility receive competency validation on environmental cleaning (check all that apply)? | * Yes, on hire * Yes, annually * Yes, other interval: * No |
| Does your facility have a system to ensure that cleaning supplies are readily available and restocked? | Yes / No |
| ***Unit/Facility Quality Improvement Activities*** | |
| How often does the infection preventionist visit the unit(s) routinely? | * Daily * Weekly * Monthly * Quarterly * Never |
| Does the infection preventionist participate in the facility’s patient safety/quality improvement meetings? | Yes / No |
| Does the infection preventionist participate in rounds to assess compliance with the following at least quarterly: | Y/N Hand hygiene  Y/N Compliance with the Centers for Disease Control and Prevention’s (CDC) contact isolation precautions or enhanced barrier precautions  Y/N Other: |
| Is there a mechanism in place for systematic analysis and proactive learning from harmful events or events with potential of harm as raised by frontline staff (other than Morbidity and Mortality conferences or assessments/official Root Cause Analyses) | Yes / No |

**Supplemental Interventions Relevant to MRSA Prevention:**

|  |  |
| --- | --- |
| ***Antimicrobial Stewardship*** | |
| Are there antibiotic stewardship (AS) processes in place to reduce use of unnecessary antibiotics? | Yes / No |
| If yes, indicate which of the following are implemented: (check all that apply) | * Checklists/algorithms/guidelines regarding indications for sending cultures * Checklists/algorithms/guidelines regarding indications for starting antibiotics * Checklists/algorithms/guidelines regarding appropriate duration of antibiotics * Daily time out by team to assess antibiotic use * Post-prescription review and feedback * Order sets for common infectious disease syndromes * Activities to reduce the use of vancomycin * Activities to reduce the use of fluoroquinolones |